Prevalence and Effect of Lifestyle Modification on Clinical Outcomes and Cost-effectiveness Ratio for Sarcopenia
Prevalence and the Effect of Lifestyle Modification Project (LMP) on Clinical Outcomes and Cost-effectiveness Ratio for Sarcopenia in Chinese Adults and Elderly: a Multicenter Randomized Controlled Trail
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Kang Yu
- Phone Number: +86 10 69155550
- Email: yuk1997@sina.com
Study Locations
-
-
-
Beijing, China
- Recruiting
- Peking Union Medical College Hospital
-
Contact:
- Kang Yu
- Phone Number: +86 13801130457
- Email: yuk1997@sina.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- age>=18 year The participants must have basic cognitive function and communication Must be able to provide a written informed consent
Exclusion Criteria:
- age<18 year Concurrent severe cardiac disease, unstable diabetes mellitus,uncontrolled chronic disease,liver and renal failer, which may significantly interfere with study compliance.
Participants received any drugs or supplements known to influence effcet size,such as protein powder, calcium, or vitamin D before the 3 months preceding the study. Participants with electronic or mental device
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: nutritional intervention
This group received multi-dimensional intensive nutritional intervention for 3 month, which included whey (30g/d,plus three times every week ),vitamin D (1000IU) and omega-3 fatty acid (DHA 1200mg and EPA 800mg).
|
The intervention is made up of nutrition supplements and dietary pattern modification, which includes whey 30g/d(plus three times every week),vitamin D 1000IU, omega-3 fatty acid (DHA1200mg and EPA 800mg)
|
|
Experimental: resistance training program
This group received resistance training program which is made up warm-up exercise, muscle strength training and relaxing.
|
The training program involve warm-up exercise, muscle strength training and relaxing
|
|
Experimental: lifestyle modification project
This group receive multi-dimensional intensive nutritional intervention and resistance training program.
|
Lifestyle modification project is made up of multi-dimensional intensive nutritional intervention and resistance training
|
|
Placebo Comparator: control
This group receive nutritional consulting,which involve dietary pattern modification and protein intake standardization.
|
The intervention involve dietary pattern modification and protein intake standardization
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
relative skeletal muscle index
Time Frame: 3 months
|
RSMI(Unit: kg/m2)is defined as muscle mass
|
3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hand grip
Time Frame: 3 months
|
HG(Unit: kg)is defined as muscle strength
|
3 months
|
|
gait speed
Time Frame: 3 months
|
GP(Unit: s)is defined as physical activity level
|
3 months
|
|
quality of life on EQ-5D scale
Time Frame: 3 months
|
Scores range from 0 [worse] to 1[best](Unit on a scale)
|
3 months
|
|
The rate of fracture
Time Frame: 3 months
|
rate of participants with fracture due to fall(Unit: %)
|
3 months
|
|
the change of physical function on frail index
Time Frame: 3 months
|
Scores range from 0 [normal] to 1[unhealth](Unit on a scale)
|
3 months
|
|
the rate of infection complication
Time Frame: 3 months
|
Rate of participants with infection complication due to sarcopenia(Unit: %)
|
3 months
|
|
mortality rate
Time Frame: 3 months
|
Rate of participants mortality(Unit: %)
|
3 months
|
|
medical cost on cost-effectiveness ratio
Time Frame: 3 months
|
the lower cost,the higher effectiveness(Unit: %)
|
3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Kang Yu, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College
Publications and helpful links
General Publications
- Li Z, Cui M, Yu K, Zhang XW, Li CW, Nie XD, Wang F. Effects of nutrition supplementation and physical exercise on muscle mass, muscle strength and fat mass among sarcopenic elderly: a randomized controlled trial. Appl Physiol Nutr Metab. 2021 May;46(5):494-500. doi: 10.1139/apnm-2020-0643. Epub 2020 Nov 20.
- Li CW, Yu K, Shyh-Chang N, Li GX, Jiang LJ, Yu SL, Xu LY, Liu RJ, Guo ZJ, Xie HY, Li RR, Ying J, Li K, Li DJ. Circulating factors associated with sarcopenia during ageing and after intensive lifestyle intervention. J Cachexia Sarcopenia Muscle. 2019 Jun;10(3):586-600. doi: 10.1002/jcsm.12417. Epub 2019 Apr 10.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PUMCH344801
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.